Palace: Duterte prefers to get China’s Sinopharm vaccine | Inquirer News

Palace: Duterte prefers to get China’s Sinopharm vaccine

By: - Reporter / @DYGalvezINQ
/ 01:55 PM February 22, 2021

MANILA, Philippines — President Rodrigo Duterte prefers to get inoculated with the China-based drugmaker Sinopharm’s Covid-19 vaccine, Malacañang said Monday.

“He [President Duterte] has said that his preference is for Sinopharm,” Presidential spokesman Harry Roque said in a Palace briefing.

ADVERTISEMENT

President Duterte earlier said he prefers to get vaccines from Chinese vaccine manufacturers; however, he cannot be administered with the Sinovac’s Covid-19 vaccine because it is not recommended for senior citizens.

FEATURED STORIES

The Food and Drug Administration (FDA), which has granted the Sinovac vaccine an emergency use authorization, said it can only be given to clinically healthy individuals between the age of 18 to 59 years old.

President Duterte is now 75 years old.

Duterte’s close-in security detail had been inoculated with the Sinopharm vaccine, which was said to be donated, last year sans an emergency use authorization from the FDA, Presidential Security Group commander Brig. Gen. Jesus Durante III earlier admitted.

President Duterte said he was not aware that his security detail has been inoculated; however, he earlier revealed that many people in the Philippines have already received China’s Sinopharm vaccine.

The FDA has issued a compassionate use license for 10,000 doses of Sinopharm vaccine at the request of the PSG.

Sinopharm is a pharmaceutical firm run by the Chinese government.

JE
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: COVID-19 Vaccine, Rodrigo Duterte, Sinopharm

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.